

January 2, 2024  
Web Announcement 3252

## Drug Use Review (DUR) Board Approves Changes for Physician Administered Drugs (PAD)

The Nevada Medicaid Drug Use Review (DUR) Board met on July 27, 2023 and voted to approve the following changes for physician administered drugs (PAD). The PAD Prior Authorization Program took effect on July 1, 2023 (see [Web Announcement 3041](#) for full details).

Drug Class/Program	Changes
Opdivo® (nivolumab))	Approval of clinical criteria
pemetrexed	Approval of clinical criteria
Perjeta® (pertuzumab)	Approval of clinical criteria
ranibizumab	Approval of clinical criteria
rituximab IV	Approval of clinical criteria
rituximab SQ	Approval of clinical criteria
SCIG (immune globulin SQ)	Approval of clinical criteria
Soliris® (eculizumab)	Approval of clinical criteria
Susvimo® (ranibizumab)	Approval of clinical criteria
Tecentriq® (atezolizumab)	Approval of clinical criteria
trastuzumab IV	Approval of clinical criteria
trastuzumab SQ	Approval of clinical criteria
Ultomiris® (ravulizumab-cwvz)	Approval of clinical criteria
Yervoy® (ipilimumab)	Approval of clinical criteria
Zynlonta® (loncastuximab tesirine-lpyl)	Approval of clinical criteria

Prior Authorization forms may be found on the below webpages:  
<https://www.mrxgateway.com/> (medical pharmacy/physician administered drugs)